Skip to main content
. 2017 Nov 22;33(1):165–169. doi: 10.1002/mds.27238

Figure 2.

Figure 2

Coprimary endpoints. (A) Superiority of the therapeutic window size (left) and noninferiority of UPDRS III (right) at a short‐pulse width. Error bars represent ± 1 standard error. (B) Side effect observed at threshold during the therapeutic measurement. The most common side effects were dysarthria and muscle twitch related to pyramidal tract activation. [Color figure can be viewed at wileyonlinelibrary.com]